Celebrating 10 Years of Trusted News Discovery
One News Page
> >

Genocea Announces Positive Interim Immunogenicity Data from GEN-009 Neoantigen Vaccine Phase 1/2a Clinical Trial

GlobeNewswire Thursday, 16 May 2019
*Post-vaccination immune responses detected to 93% of vaccine neoantigensin first three patients analyzed*

*Additional data to be presented June 1^st at ASCO 2019 and discussed on a
conference call and webcast on June 3^rd*

CAMBRIDGE, Mass., May 16, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced the first clinical results from its ongoing Phase 1/2a trial for GEN-009, the company’s lead neoantigen vaccine candidate. Genocea employs its ATLAS™ platform for patient-specific neoantigen selection, using each patient’s own T cells to identify the neoantigens to which each patient mounts anti-tumor cytokine responses.

“To date, we have analyzed full immune response data from three patients following their priming series of three vaccinations and have detected immune responses to 93% of the total administered neoantigens, a response rate that would be best-in-class if seen across the full vaccinated cohort,” said Tom Davis, M.D., Genocea’s Chief Medical Officer. “We are studying a diverse group of patients and, despite this variability, we are seeing consistently broad immune responses, including ex vivo CD8^+ T cell responses, which have not previously been detected after monotherapy with a neoantigen vaccine. We expect to present more detailed immunogenicity and safety data from these and additional patients at the upcoming meeting of the American Society of Clinical Oncology (ASCO).”

*ASCO POSTER SESSION: Developmental Immunotherapy and Tumor Immunobiology*
Poster Board: #255 • *Abstract 2611

*Title:            A phase 1/2a study of GEN-009, a neoantigen vaccine based on autologous peptide immune responses*
Presenter:    Roger B. Cohen, M.D., University of Pennsylvania Perelman School of Medicine
Date:            Saturday, June 1, 8:00 AM - 11:00 AM Central Time
Location:      Hall A

*Note: The abstract was submitted prior to the availability of the immunogenicity data being reported today.

*Conference Call and Webcast – June 3^rd at 8:30 am ET*
Genocea will host a conference call and webcast to discuss the clinical results presented at ASCO at 8:30 am ET on June 3, 2019. Interested participants may access the conference call by dialing (844) 826-0619 (domestic) or (315) 625-6883 (international) and referring to conference ID number 9068006. To join the live webcast, please visit the presentation page of the investor relations section of the Genocea website at A webcast replay of the conference call will be available on the Genocea website beginning approximately two hours after the event and will be archived for 90 days.

*About Genocea Biosciences, Inc.*
Genocea is a biopharmaceutical company developing personalized cancer immunotherapies. Our unique ATLAS™ technology platform allows us to identify immunotherapy targets based on each person’s tumor antigen-specific T cell responses. Using ATLAS, we can both optimize neoantigens for inclusion in our immunotherapies and exclude so-called “inhibitory” antigens that appear to exert an immunosuppressive effect on the patient. We are advancing complementary programs built from ATLAS insights:  GEN-009, our neoantigen vaccine candidate for which we are conducting a Phase 1/2a clinical trial across a variety of solid tumor types, and GEN-011, our neoantigen-specific adoptive T cell therapy, for which we intend to file an Investigational New Drug Application in the first half of 2020. To learn more, please visit

*Forward-Looking Statements*
This press release includes forward-looking statements, including statements relating to expectations of additional immunogenicity and safety data from our Phase 1/2a clinical trial for GEN-009 and intentions for filing an Investigational New Drug Application for GEN-011, within the meaning of the Private Securities Litigation Reform Act. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Genocea cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties that change over time. Applicable risks and uncertainties include those identified under the heading "Risk Factors" included in Genocea's Annual Report on Form 10-K for the year ended December 31, 2018 and any subsequent SEC filings. These forward-looking statements speak only as of the date of this press release and Genocea assumes no duty to update forward-looking statements, except as may be required by law.

Jennifer LaVin
[email protected]

You Might Like

Recent related news from verified sources

Arbutus Biopharma shares soar on Phase 1a/1b trial for its AB-729 hepatitis B drug

Arbutus Biopharma Corporation (NASDAQ:ABUS), an industry-leading hepatitis B Virus (HBV) therapeutic solutions company, announced news Thursday that it has...
Proactive Investors Also reported by •GlobeNewswireBusiness Wire

NantKwest Launches First-in-class, First-in-human Phase I Clinical Trial With a Targeted PD-L1 t-haNK Cell Therapy in Patients With Solid Tumors

NantKwest Launches First-in-class, First-in-human Phase I Clinical Trial With a Targeted PD-L1 t-haNK Cell Therapy in Patients With Solid Tumors
CULVER CITY, Calif.--(BUSINESS WIRE)--NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the...
Business Wire

Ironwood and Allergan Report Positive Topline Data from Phase IIIb Trial of LINZESS® (linaclotide) in Adults with Irritable Bowel Syndrome with Constipation (IBS-C)

Ironwood and Allergan Report Positive Topline Data from Phase IIIb Trial of LINZESS® (linaclotide) in Adults with Irritable Bowel Syndrome with Constipation (IBS-C)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Allergan plc (NYSE:AGN) today announced positive topline data from a Phase...
Business Wire Also reported by •GlobeNewswire

ADC Therapeutics Presents Clinical Data on ADCT-402 and ADCT-301 in Subtypes of Relapsed or Refractory Lymphoma at the 15th International Conference on Malignant Lymphoma

Ongoing pivotal Phase II clinical trial of ADCT-402 in patients with relapsed or refractory diffuse large B-cell lymphoma anticipated to complete enrollment in...

Other recent news in Press Releases

GXChain is Leading to Explosion in Blockchain-based Trusted Computing BUSINESSEvotec, Sensyne HEALTH, The University Of Oxford, OSI, and OUI Create New Bridge Partnership 'LAB10X' In Digital HEALTH
Environmentally friendly: One News Page is hosted on servers powered solely by renewable energy
© 2019 One News Page Ltd. All Rights Reserved.
About us  |  Contact us  |  Disclaimer  |  Press Room  |  Terms & Conditions  |  Content Accreditation
 RSS  |  News for my Website  |  Free news search widget  |  In the News  |  DMCA / Content Removal  |  Privacy & Data Protection Policy
How are we doing? FeedbackSend us your feedback  |   LIKE us on Facebook   FOLLOW us on Twitter  •  FOLLOW us on Pinterest
One News® is a registered trademark of One News Page Ltd.